Potential Diabetes Target Markets
SYMLIN
PLUS Multiple Insulin Injections
Beta-cell function
Disease Progression
Diet Exercise
Normal
Absent
CLINICAL STUDIES
PLUS
Oral agents
Failing Oral Agents
PLUS Single
Insulin Injection
Type 1
Type 2
Previous slide
Next slide
Back to first slide
View graphic version